This resource is a video abstract of a research paper created by Research Square on behalf of its authors. It provides a synopsis that's easy to understand, and can be used to introduce the topics it covers to students, researchers, and the general public. The video's transcript is also provided in full, with a portion provided below for preview:

"Leukemia relapse after conventional treatments is difficult to treat and has high patient mortality. Relapse is driven by the reawakening of previously quiescent cancer cells. Traditional treatments are ineffective against quiescent cells, as they instead target rapidly dividing cells. A new study investigated a potential dual-target treatment, C212, in cell culture. C212 is a derivative of curcumin, a compound that has shown anticancer properties in previous research. C212 was effective against both growing and quiescent leukemia cells. C212 drives quiescent leukemia cells deeper into dormancy by increasing their exit threshold, and then kills these deep-quiescent cells. This differs from previous strategies that awaken quiescent cells to kill, which runs the risk of wakening treatment-resistant subpopulation of cells. Molecular docking and experimental analyses showed that C212 could bind to Hsp90 and interferes with its function..."

The rest of the transcript, along with a link to the research itself, is available on the resource itself.

This resource is a video abstract of a research paper created by Research Square on behalf of its authors. It provides a synopsis that's easy to understand, and can be used to introduce the topics it covers to students, researchers, and the general public. The video's transcript is also provided in full, with a portion provided below for preview:

"Acute lymphoblastic leukemia (ALL) is the most common cancer in children, and 85% of cases are B-cell ALL (B-ALL). Although the prognosis is usually good, 10–15% of patients have relapsing or refractory disease, which can lead to poor outcomes. To aid in the development of better treatments for these patients, a new study investigated the role of netrin-1 in B-ALL, as this axon guidance protein has been linked to tumorigenesis in many cancers. In the study, serum netrin-1 levels were higher in children with B-ALL than in children without cancer, and when the children with B-ALL were grouped by risk stratification, the high- and intermediate-risk groups had higher netrin-1 levels than the low-risk group. In vitro, recombinant netrin-1 prevented apoptosis of B-ALL cells, thus supporting cancer cell survival by interacting with the receptor Unc5b to activate the FAK-MAPK pathway. However, netrin-1 did not affect B-ALL cell migration..."

The rest of the transcript, along with a link to the research itself, is available on the resource itself.

This resource is a video abstract of a research paper created by Research Square on behalf of its authors. It provides a synopsis that's easy to understand, and can be used to introduce the topics it covers to students, researchers, and the general public. The video's transcript is also provided in full, with a portion provided below for preview:

"Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, and it tends to have a poor prognosis. For NSCLC with EGFR gene mutation, the tyrosine kinase inhibitor osimertinib can be an effective targeted therapy. However, patients usually develop resistance to osimertinib over time, often due to additional changes in the EGFR gene. For example, tumors can develop mutations in exons 18 and 20 of EGFR that reduce osimertinib's ability to bind to its target. In addition, the EGFR gene can become amplified, leading to extra copies in the genome. This leads to abnormally high amounts of the EGFR protein, overwhelming osimertinib and triggering signaling pathways that promote cancer progression. Over time, tumor cells with resistance-promoting mutations can replace the original drug-sensitive cells that are killed off by osimertinib. Combination therapies or next-generation tyrosine kinase inhibitors might help address these limitations of osimertinib..."

The rest of the transcript, along with a link to the research itself, is available on the resource itself.

Psychology is designed to meet scope and sequence requirements for the single-semester introduction to psychology course. The book offers a comprehensive treatment of core concepts, grounded in both classic studies and current and emerging research. The text also includes coverage of the DSM-5 in examinations of psychological disorders. Psychology incorporates discussions that reflect the diversity within the discipline, as well as the diversity of cultures and communities across the globe.Senior Contributing AuthorsRose M. Spielman, Formerly of Quinnipiac UniversityContributing AuthorsKathryn Dumper, Bainbridge State CollegeWilliam Jenkins, Mercer UniversityArlene Lacombe, Saint Joseph's UniversityMarilyn Lovett, Livingstone CollegeMarion Perlmutter, University of Michigan

By the end of this section, you will be able to:Recognize the goal of substance-related and addictive disorders treatmentDiscuss what makes for effective treatmentDescribe how comorbid disorders are treated